Search Our Site

News tagged with:

"hepatitis-c"

Report Cites Liver Failure Risk With New Hepatitis C Drugs

A new report questions the safety of some of the new drugs found to cure hepatitis C, in light of findings of liver failure and injury. But hepatitis C virus (HCV) experts say the findings are inconclusive, should be interpreted with great caution, and should not influence prescribing. Researchers at the Institute for Safe Medication... Read More »

Read More →

A new report questions the safety of some of the new drugs found to cure hepatitis C, in light of findings of liver failure and injury. But hepatitis C virus (HCV) experts say the findings are inconclusive, should be interpreted with great caution, and should not influence prescribing. Researchers at the Institute for Safe Medication… Read More »

[...]

Read More

FDA to Review Combo Drug Considered a Salvage Therapy for HCV Patients

Gilead Sciences announced the submission of a New Drug Application (NDA) for a once-daily single tablet regimen containing sofosbuvir 400mg, velpatasvir 100mg, and voxilaprevir 100mg (SOF/VEL/VOX) for the treatment of patients with direct-acting antiviral (DAA)-experienced chronic hepatitis C virus (HCV) infection. The NDA submission includes data to support the SOF/VEL/VOX regimen for 12 weeks in DAA-experienced... Read More »

Read More →

Gilead Sciences announced the submission of a New Drug Application (NDA) for a once-daily single tablet regimen containing sofosbuvir 400mg, velpatasvir 100mg, and voxilaprevir 100mg (SOF/VEL/VOX) for the treatment of patients with direct-acting antiviral (DAA)-experienced chronic hepatitis C virus (HCV) infection. The NDA submission includes data to support the SOF/VEL/VOX regimen for 12 weeks in DAA-experienced… Read More »

[...]

Read More

Help with the high cost of hepatitis C drugs

After legal battles and lobbying efforts, thousands of people with hepatitis C are gaining earlier access to expensive drugs that can cure this condition. States that limited access to the medications out of concern over sky-high prices have begun to lift those restrictions – many, under the threat of legal action.   And commercial insurers such... Read More »

Read More →

After legal battles and lobbying efforts, thousands of people with hepatitis C are gaining earlier access to expensive drugs that can cure this condition. States that limited access to the medications out of concern over sky-high prices have begun to lift those restrictions – many, under the threat of legal action.   And commercial insurers such… Read More »

[...]

Read More

The scarcity of kidneys for transplantation and high mortality among patients on the waiting list have led some patients to accept kidney transplants that carry elevated risks of transmitting infections or cancer. In certain cases, such as the transmission of cytomegalovirus, physicians can anticipate these events and institute preventive measures. But transplant teams often discard… Read More »

[...]

Read More

Originally posted on: Mercknewsroom.com C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free Hepatitis C Treatment Regimen in Treatment-Naïve and Treatment-Experienced Patients with Advanced Chronic Kidney Disease Infected with Hepatitis C Virus Genotype 1  Thursday, April 23, 2015 3:30 am EDT “In this trial, the first to investigate an all-oral ribavirin-free treatment regimen in treatment-naïve… Read More »

[...]

Read More
Categories
Archives